Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors | MicrobiomeTrials← Back to trialsNCT06781983
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-01-24Est. Completion: 2028-04
Enrollment target: 145 participants Locations- Massachusetts General Hospital - Boston, Boston, Massachusetts, United States
- John Theurer Cancer Center, Hackensack, New Jersey, United States
- Mount Sinai Tisch Cancer Center, New York, New York, United States
- NEXT Oncology - Dallas, Dallas, Texas, United States
- NEXT Oncology - Virginia, Fairfax, Virginia, United States
- Centre Léon Bérard, Lyon, France
- Gustave Roussy Cancer Institute, Villejuif, France
Other microbiome trials you might be interested in
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell CarcinomaLocally Recurrent Laryngeal Squamous Cell CarcinomaLocally Recurrent Oral Cavity Squamous Cell CarcinomaLocally Recurrent Oropharyngeal Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell Carcinoma
Metastatic Melanoma
Metastatic Oral Cavity Squamous Cell Carcinoma
Metastatic Oropharyngeal Squamous Cell Carcinoma
Recurrent Melanoma
Stage III Hypopharyngeal Carcinoma AJCC v8
Stage III Laryngeal Cancer AJCC v8
Stage III Lip and Oral Cavity Cancer AJCC v8
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage IV Hypopharyngeal Carcinoma AJCC v8
Stage IV Laryngeal Cancer AJCC v8
Stage IV Lip and Oral Cavity Cancer AJCC v8
Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Unresectable Melanoma
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in tr…
Phoenix, United StatesEst. completion Jan 1, 2027
Head and Neck Neoplasms
This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in c…
La Jolla, United StatesEst. completion Jul 25, 2024
Cancer Harboring BRAF AlterationsHGGLGGSolid Tumors
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF a…
Beverly Hills, United StatesEst. completion Dec 31, 2027